Kendra Vehik1, Ezio Bonifacio2,3, Åke Lernmark4, Liping Yu5, Alistair Williams6, Desmond Schatz7, Marian Rewers5, Jin-Xiong She8, Jorma Toppari9,10, William Hagopian11, Beena Akolkar12, Anette G Ziegler2,13, Jeffrey P Krischer14. 1. Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL kendra.vehik@epi.usf.edu. 2. Forschergruppe Diabetes e.V., Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany. 3. DFG Center for Regenerative Therapies Dresden, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. 4. Department of Clinical Sciences, Lund University/CRC, Skane University Hospital, Malmö, Sweden. 5. Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO. 6. Diabetes and Metabolism, Translational Health Sciences, University of Bristol, Bristol, U.K. 7. Diabetes Center of Excellence, University of Florida, Gainesville, FL. 8. Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA. 9. Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland. 10. Department of Pediatrics, Turku University Hospital, Turku, Finland. 11. Pacific Northwest Diabetes Research Institute, Seattle, WA. 12. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 13. Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, Neuherberg, Germany. 14. Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL.
Abstract
OBJECTIVE: The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study. RESEARCH DESIGN AND METHODS: Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody. RESULTS: There were 608 children who developed a single first-appearing autoantibody (IAA, n = 282, or GADA, n = 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88-1.42; P = 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78-10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10-29.29; P < 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61-10.95; P < 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04-4.65; P < 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D. CONCLUSIONS: The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D.
OBJECTIVE: The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study. RESEARCH DESIGN AND METHODS: Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody. RESULTS: There were 608 children who developed a single first-appearing autoantibody (IAA, n = 282, or GADA, n = 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88-1.42; P = 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78-10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10-29.29; P < 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61-10.95; P < 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04-4.65; P < 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D. CONCLUSIONS: The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D.
Authors: L Yu; M Rewers; R Gianani; E Kawasaki; Y Zhang; C Verge; P Chase; G Klingensmith; H Erlich; J Norris; G S Eisenbarth Journal: J Clin Endocrinol Metab Date: 1996-12 Impact factor: 5.958
Authors: J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122
Authors: Janet M Wenzlau; Ong Moua; Suparna A Sarkar; Liping Yu; Marian Rewers; George S Eisenbarth; Howard W Davidson; John C Hutton Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: Liping Yu; David C Boulware; Craig A Beam; John C Hutton; Janet M Wenzlau; Carla J Greenbaum; Polly J Bingley; Jeffrey P Krischer; Jay M Sosenko; Jay S Skyler; George S Eisenbarth; Jeffrey L Mahon Journal: Diabetes Care Date: 2012-03-23 Impact factor: 19.112
Authors: Jorma Ilonen; Anna Hammais; Antti-Pekka Laine; Johanna Lempainen; Outi Vaarala; Riitta Veijola; Olli Simell; Mikael Knip Journal: Diabetes Date: 2013-07-08 Impact factor: 9.461
Authors: Karla Fabiana Brasil Gomes; Cintia Semzezem; Rodolfo Batista; Rosa Tsuneshiro Fukui; Aritania Sousa Santos; Márcia Regina Correia; Maria Rita Passos-Bueno; Maria Elizabeth Rossi da Silva Journal: Sci Rep Date: 2017-03-16 Impact factor: 4.379
Authors: Anna E Long; Isabel V Wilson; Dorothy J Becker; Ingrid M Libman; Vincent C Arena; F Susan Wong; Andrea K Steck; Marian J Rewers; Liping Yu; Peter Achenbach; Rosaura Casas; Johnny Ludvigsson; Alistair J K Williams; Kathleen M Gillespie Journal: Diabetologia Date: 2018-03-12 Impact factor: 10.122
Authors: Carina Törn; David Hadley; Hye-Seung Lee; William Hagopian; Åke Lernmark; Olli Simell; Marian Rewers; Anette Ziegler; Desmond Schatz; Beena Akolkar; Suna Onengut-Gumuscu; Wei-Min Chen; Jorma Toppari; Juha Mykkänen; Jorma Ilonen; Stephen S Rich; Jin-Xiong She; Andrea K Steck; Jeffrey Krischer Journal: Diabetes Date: 2014-11-24 Impact factor: 9.337
Authors: Anna Casu; Paul J Grippo; Clive Wasserfall; Zhaoli Sun; Peter S Linsley; Jessica A Hamerman; Brian T Fife; Adam Lacy-Hulbert; Frederico G S Toledo; Phil A Hart; Georgios I Papachristou; Melena D Bellin; Dhiraj Yadav; Maren R Laughlin; Mark O Goodarzi; Cate Speake Journal: Pancreas Date: 2022-07-01 Impact factor: 3.243
Authors: Kenney Ng; Vibha Anand; Harry Stavropoulos; Riitta Veijola; Jorma Toppari; Marlena Maziarz; Markus Lundgren; Kathy Waugh; Brigitte I Frohnert; Frank Martin; Olivia Lou; William Hagopian; Peter Achenbach Journal: Diabetologia Date: 2022-10-05 Impact factor: 10.460
Authors: Maria Månsson Martinez; Lampros Spiliopoulos; Marlena Maziarz; Carina Törn; Falastin Salami; Daniel Agardh; Jorma Toppari; Åke Lernmark; Jukka Kero; Riitta Veijola; Päivi Tossavainen; Sauli Palmu; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Helena Elding Larsson; Mikael Knip Journal: Clin Diabetes Endocrinol Date: 2022-01-05